These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 7371361)

  • 1. Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding.
    Verbeeck RK; De Schepper PJ
    Clin Pharmacol Ther; 1980 May; 27(5):628-35. PubMed ID: 7371361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible mechanisms for reduced plasma clearance of diflunisal in rat experimental renal failure.
    Lin JH; Ulm EH; Duggan DE
    J Pharmacol Exp Ther; 1986 Sep; 238(3):978-84. PubMed ID: 3746671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein binding of salicylate in uremic and normal plasma.
    Borgå O; Cederlöf IO; Ringberger VA; Norlin A
    Clin Pharmacol Ther; 1976 Oct; 20(4):464-75. PubMed ID: 975718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid.
    Odar-Cederlöf I; Borga O
    Clin Pharmacol Ther; 1976 Jul; 20(1):36-47. PubMed ID: 1277724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma protein binding and interaction studies with diflunisal, a new salicylate analgesic.
    Verbeeck RK; Boel A; Buntinx A; De Schepper PJ
    Biochem Pharmacol; 1980 Feb; 29(4):571-6. PubMed ID: 7370051
    [No Abstract]   [Full Text] [Related]  

  • 6. In-vitro study on the competitive binding of diflunisal and uraemic toxins to serum albumin and human plasma using a potentiometric ion-probe technique.
    Davilas A; Koupparis M; Macheras P; Valsami G
    J Pharm Pharmacol; 2006 Nov; 58(11):1467-74. PubMed ID: 17132209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of the binding characteristics of chlorophenoxyisobutyric acid to serum proteins in chronically uremic patients : influence of dialysis and heparine (author's transl)].
    Lacour B; Di Giulio S; Nicolaï A; Drüeke T; Debray M; Boulu RG
    Nephrologie; 1982; 3(1):19-22. PubMed ID: 7088259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma protein binding of zolpidem in liver and renal insufficiency.
    Pacifici GM; Viani A; Rizzo G; Carrai M; Ganansia J; Bianchetti G; Morselli PL
    Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):439-43. PubMed ID: 3198298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivity of diflunisal acyl glucuronide in human and rat plasma and albumin solutions.
    Watt JA; Dickinson RG
    Biochem Pharmacol; 1990 Mar; 39(6):1067-75. PubMed ID: 2322294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of uremia and hemodialysis on the plasma protein binding of tolmetin.
    Pritchard JF; O'Neill PJ; Affrime MB; Lowenthal DT
    Pharmacology; 1984; 29(6):312-9. PubMed ID: 6505005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced in vitro binding of tryptophan by plasma in uremia.
    de Torrente A; Glazer GB; Gulyassy P
    Kidney Int; 1974 Oct; 6(4):222-9. PubMed ID: 4427418
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal.
    Erikson LO; Wåhlin-Boll E; Odar-Cederlöf I; Lindholm L; Melander A
    Eur J Clin Pharmacol; 1989; 36(2):165-74. PubMed ID: 2721541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of diflunisal on the pharmacokinetics of oxazepam.
    van Hecken AM; Tjandramaga TB; Verbesselt R; de Schepper PJ
    Br J Clin Pharmacol; 1985 Sep; 20(3):225-34. PubMed ID: 4041343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma protein carbamylation and decreased acidic drug protein binding in uremia.
    Erill S; Calvo R; Carlos R
    Clin Pharmacol Ther; 1980 May; 27(5):612-8. PubMed ID: 7371359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma aminothiol oxidation in chronic hemodialysis patients.
    Himmelfarb J; McMenamin E; McMonagle E
    Kidney Int; 2002 Feb; 61(2):705-16. PubMed ID: 11849414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA; Evenson MA; Sarver KP; Wagnild JP
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences.
    Perna AF; Ingrosso D; Satta E; Lombardi C; Galletti P; D'Aniello A; De Santo NG
    J Am Soc Nephrol; 2004 Oct; 15(10):2747-54. PubMed ID: 15466280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum uremic toxins from patients with chronic renal failure displace the binding of L-tryptophan to human serum albumin.
    Mingrone G; De Smet R; Greco AV; Bertuzzi A; Gandolfi A; Ringoir S; Vanholder R
    Clin Chim Acta; 1997 Apr; 260(1):27-34. PubMed ID: 9101098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cortisol binding in uremic plasma. II. Decreased cortisol binding to albumin.
    Rosman PM; Benn R; Kay M; Wallace EZ
    Nephron; 1984; 37(4):229-31. PubMed ID: 6462312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure.
    Olsen GD; Bennett WM; Porter GA
    Clin Pharmacol Ther; 1975 Jun; 17(6):677-84. PubMed ID: 1095281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.